Providence Cancer Institute
Trending Articles
Related Content
Research & Development
Nanobiotix partners with the Providence Cancer Institute
Nanobiotix announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumours and activation by radiotherapy